HMG-CoA reductase inhibitors

US7659281B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Philip D. Stein · Pennington, US
• Steven P. Seitz · Swarthmore, US
• David J. Carini · Wilmington, US
• Yan Shi · Flourtown, US
• Jeffrey A. Robl · Newtown, US
• Jay A. Markwalder · New London, US
• Chunhong He · Boothwyn, US

Key dates

• Filing date: Apr 24, 2007
• Grant date: Feb 9, 2010
• Expiry date: Aug 8, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosiswherein variables A and B are defined herein.